Fibrinogen-like protein-1 (FGL-1) may play a key role in the onset of autoimmunity by suppressing T cell activation in primary Sjögren disease, according to findings from Otsuka et al. Their study, which examined the influence of interorgan communication on disease pathogenesis in mice models and patients with primary Sjögren disease, may help facilitate novel diagnostic or therapeutic strategies targeting immune checkpoint molecules in autoimmune diseases.
ACR Convergence 2025 speakers reviewed new fibromyalgia insights, from the first new drug approval since 2009 to nociplastic pain concepts & cognitive behavioral therapy.
At a scientific session of ACR Convergence 2025, Alexis Ogdie, MD, discussed new and forthcoming treatments for psoriatic arthritis.
Incoming ARP President Dr. Rebecca Cleveland discusses her plans for advocacy, ACR/ARP collaboration, & tackling workforce shortages in rheumatology.
Incoming ACR President Will Harvey shares his strategy for fighting reimbursement cuts, funding threats & workforce shortages through advocacy & member engagement.
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis are presented here.
ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.
Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.